The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | 8,713 | - |
| Stock-based compensation | 432 | 342 |
| Net change in fair value of trading marketable securities | 0 | 0 |
| Net loss | - | -5,593 |
| Net change in fair value of digital assets | 75 | - |
| Non-cash lease expense | 9 | 17 |
| Amortization of debt discounts and debt issuance costs | 83 | 54 |
| Prepaid expenses and other current assets | -53 | -58 |
| Accounts payable and accrued liabilities | -906 | 3,046 |
| Accounts payable - related parties | 7 | -36 |
| Accrued interest | 28 | 18 |
| Fixed cash payments related to operating leases | -9 | -17 |
| Net cash used in operating activities | -3,498 | -2,111 |
| Purchase of digital assets | 250 | - |
| Investment in trading marketable securities | 0 | 0 |
| Proceeds from disposition of marketable securities | 0 | 0 |
| Net cash (used in) provided by investing activities | -250 | 0 |
| Proceeds from issuance of common stock for cash, net | 3,312 | 1,079 |
| Proceeds from issuance of convertible notes, net | 0 | 737 |
| Proceeds from exercise of warrants | 132 | - |
| Net cash provided by financing activities | 3,444 | 1,816 |
| Effect of exchange rate changes on cash | -42 | 23 |
| Net change in cash and cash equivalents | -346 | -272 |
| Cash and cash equivalents at beginning of period | 2,338 | - |
| Cash and cash equivalents at end of period | 1,720 | - |
ARTELO BIOSCIENCES, INC. (ARTL)
ARTELO BIOSCIENCES, INC. (ARTL)